References
1
Bagshawe KD.
Tumor Marker Update.
1997,
34:
220
2
Melton RG.
Sherwood RF.
J. Natl. Cancer Inst.
1996,
21:
153
3
Niculescu-Duvaz I.
Springer CJ.
Adv. Drug Delivery Rev.
1997,
26:
151
4
Jungheim LN.
Shepherd TA.
Chem. Rev.
1994,
94:
1553
5a
Jacquesy J.-C.
Gesson J.-P.
Monneret C.
Mondon M.
Renoux B.
Florent J.-C.
Koch M.
Tillequin F.
Sedlacek HH.
Gerken M.
Kolar C.
Gaudel G.
Bosslet K.
Czech J.
Hoffmann D.
Seemann G.
Eur. Pat. Appl.
1992,
EP 511:
917 ; Chem. Abstr. 1994, 120, 271070S
5b
Florent J.-C.
Dong X.
Gaudel G.
Mitaku S.
Monneret C.
Gesson J.-P.
Jacquesy J.-C.
Mondon M.
Renoux B.
Andrianomenjanahary S.
Michel S.
Koch M.
Tillequin F.
Gerken M.
Czech J.
Straub R.
Bossley K.
J. Med. Chem.
1998,
41:
3572
6
Bosslet K.
Czech J.
Lorenz P.
Sedlacek HH.
Schuermann M.
Seemann G.
Br. J. Cancer
1992,
65:
234
7
Bosslet K.
Czech J.
Hoffmann D.
Tumor Targeting
1995,
1:
45
8
Bosslet K.
Czech J.
Hoffmann D.
Cancer Res.
1994,
54:
2151
9
Schmidt F.
Florent J.-C.
Monneret C.
Straub R.
Czech J.
Gerken M.
Bosslet K.
Bioorg. Med. Chem. Lett.
1997,
7:
1071
10
Lougerstay-Madec R.
Florent J.-C.
Monneret C.
Nemati F.
Poupon MF.
Anti-Cancer Drug Design.
1998,
13:
995
11
Tietze LF.
Lieb M.
Herzig T.
Haunert F.
Schuberth I.
Bioorg. Med. Chem.
2001,
9:
1929
12a
Schmidt F.
Ugureanu I.
Duval R.
Poupon A.
Monneret C.
Eur. J. Org. Chem.
2001,
2129
12b
Desbene S.
Van Dufat-Trinh H.
Michel S.
Tillequin F.
Koch M.
Schmidt F.
Florent J.-C.
Monneret C.
Straub R.
Czech M.
Gerken M.
Bosslet K.
Anti-cancer Drug Design
1999,
14:
93
13
Papot S.
Bachmann C.
Combaud D.
Gesson J.-P.
Tetrahedron
1999,
55:
4699
14a
Bergman J.
Brynolf A.
Vuorinen E.
Tetrahedron
1986,
42:
3689
14b
Bergman J.
Norrby PO.
Sand P.
Tetrahedron
1990,
46:
6113
15
Coyne WE.
Cusic JW.
J. Med. Chem.
1968,
11:
1208
16 Preparation of 8: 6-Nitroveratryl chloroformate (85 mg, 0.30 mmol) and pyridine (0.075 mL, 0.9 mmol) were added to a stirred solution of 7 (100 mg, 0.15 mmol) in CH2Cl2 (0.65 mL) at r.t. After 3 h the mixture was worked up with a saturated solution of NaHCO3 and the aqueous layer was washed with CH2Cl2. The combined organic layers were dried (MgSO4), filtered, concentrated to dryness and the remaining yellow solid was purified by flash chromatography (petroleum ether-EtOAc 1:1) to give 8 (116 mg, 0.13 mmol, 87%). 1H NMR (300 MHz, CD3COCD3), δ: 2.04, 2.05, 2.07 (3 × s, 9 H, CH3COO), 3.26
(s, 3 H, CH3N), 3.50 (s, 3 H, OCH3), 3.70 (s, 3 H, COOCH3), 3.87 (s, 6 H, OCH3), 4.37 (d, 2 H, J = 6 Hz, CH2N), 4.65
(d, 1 H, J = 9.5 Hz, H-5), 5.00 (s, 2 H, CH2O), 5.18-5.69 (m, 6 H, H-1,2,3,4, CH2O), 6.48 (s, 1 H, Harom), 7.02 (s, 1 H, NH), 7.30-7.84 (m, 8 H, Harom) ppm; 13C NMR (75 MHz, CD3COCD3), δ: 37.9 (CH3N), 41.3 (CH2N), 53.0 (COOCH3), 56.6 (OCH3), 65.0-65.1 (CH2O), 69.9, 71.1, 72.1, 72.8 (C-2,3,4,5), 100.0 (C-1), 121.2-149.6 (Carom), 155.0-156.1 (Carom), 167.7 (COOMe), 169.5, 170.0, 170.2 (CH3CO) ppm; mp 100 °C.
17 Data for 9: [αD] = +6,4 (c 0.95, CHCl3); 1H NMR (300 MHz, CD3COCD3), δ: 3.51 (s, 3 H, CH3N), 3.59-3.62 (m, 3 H,
H-2,3,4), 3.71 (s, 3 H, COOCH3), 3.87 (s, 6 H, OCH3), 4.20 (d, 1 H, J = 9.5 Hz, H-5), 4.37 (d, 2 H, J = 6 Hz, CH2N), 5.00 (s, 2 H, CH2O), 5.33 (s, 2 H, CH2O), 5.51 (d, 1 H, J = 16 Hz, H-1), 7.00 (broad s, 1 H, HNH), 7.31-7.83 (m, 9 H, Harom) ppm; 13C NMR (75 MHz, CD3COCD3), δ: 37.9 (CH3N), 41.3 (CH2N), 52.5 (COOCH3), 56.5, 56.6 (OCH3), 65.0, 65.1 (CH2O), 72.3, 74.1, 76.4, 76.9 (C-2,3,4,5), 101.9 (C-1), 118.1-150.0 (Carom), 155.2, 157.1 (Ccarbamate), 169.5 (COOMe) ppm; mp 90 °C. The highly polar compound 10 does not lead to well resolved NMR spectra (this is observed for all glucuronylated prodrugs).
18 HPLC conditions : C-16 reverse phase column : Discovery RP amide, 5 m (15 cm × 4.6 mm) and pre-column Discovery, 5 µm, UV detection (λ 254 nm), mobile phase (acetonitrile-0.065 M acetate ammonium solution, 30:70, 1 mL min-1). Retention time: 10: 7.8 min; 4-hydroxy-3-nitrobenzyl alcohol: 3.6 min; 3 (R1 = CH3, R2 = H): 4.1 min; 6-nitroveratryl alcohol: 5.2 min; 1 (R1 = CH3, R2 = H, R3 = 6-nitroveratryl alcohol): 6.3 min.
19 We have recently shown that 2-nitro-quinone-methides are not irreversible inhibitors of bovine β-glucuronidase: Azoulay M.
Chalard F.
Gesson J.-P.
Florent J.-C.
Monneret C.
Carbohydr. Res.
2001,
332:
151